伊布替尼联合RICE或RVICI治疗儿童及年轻成人复发/难治性成熟B细胞非霍奇金淋巴瘤:SPARKLE试验
开放标签随机全球3期SPARKLE试验第2部分评估伊布替尼联合RICE或RVICI对比单用RICE/RVICI的疗效。51例1至30岁患者按2:1随机分配,主要终点无事件生存期(EFS)无显著获益:中位EFS 6.1 vs 7.0个月(HR 0.9,90%CI 0.5-1.6,P=0.387),因无效提前终止入组。
要点
- 伊布替尼联合RICE/RVICI未改善EFS:中位6.1 vs 7.0个月(HR 0.9,90%CI 0.5-1.6,P=0.387)。
- 总缓解率联合组69% vs 单用组81%,两组均有100%患者发生≥3级治疗中出现的不良事件。
- 既往接受过利妥昔单抗的患者挽救治疗普遍效果不佳,与治疗分组无关。
核心结论
- 伊布替尼联合RICE或RVICI未显示无事件生存获益,试验因无效提前终止入组。
- 在既往接受过利妥昔单抗的患者中,无论何种治疗分组,挽救治疗普遍效果不佳。
- 未观察到新的安全性信号,儿童患者伊布替尼暴露量在成人目标范围内。
研究设计与样本
- 开放标签、随机、全球3期SPARKLE试验第2部分,评估伊布替尼联合RICE或RVICI对比单用RICE/RVICI的疗效。
- 纳入1至30岁(初诊年龄<18岁)复发/难治性成熟B细胞非霍奇金淋巴瘤患者,按2:1随机分配接受伊布替尼联合或不联合RICE/RVICI。
- 主要终点为基于独立委员会确认事件的无事件生存期(EFS),共入组51例患者。
主要发现
- 中位年龄15岁;伯基特淋巴瘤、伯基特白血病和伯基特样淋巴瘤合计45%,弥漫大B细胞淋巴瘤/原发纵隔B细胞淋巴瘤占51%。
- 预设期中分析时,伊布替尼联合RICE/RVICI组 vs 单用RICE/RVICI组的中位EFS为6.1 vs 7.0个月(HR 0.9,90%CI 0.5-1.6,P=0.387),随后停止进一步入组。
- 伊布替尼联合RICE/RVICI组 vs 单用RICE/RVICI组的中位总生存期为14.1 vs 11.1个月。
- 伊布替尼联合RICE/RVICI组 vs 单用RICE/RVICI组的总缓解率为69% vs 81%,接受干细胞移植的比例为46% vs 44%。
- 两组均有100%患者发生≥3级治疗中出现的不良事件。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Part 1 results of the open-label, randomized, global phase 3 SPARKLE trial supported continued assessment of ibrutinib with either modified rituximab, ifosfamide, carboplatin, and etoposide (RICE) or rituximab, vincristine, ifosfamide, carboplatin, idarubicin, and dexamethasone (RVICI) in pediatric patients with relapsed/refractory (R/R) mature B-cell non-Hodgkin lymphoma (B-NHL). We report final results of Part 2 evaluating the efficacy of ibrutinib plus RICE or RVICI vs RICE/RVICI alone. Patients aged 1 to 30 years (initial diagnosis <18 years) were randomized 2:1 to receive ibrutinib with or without RICE/RVICI. Primary endpoint was event-free survival (EFS) based on independent committee-confirmed events. Fifty-one patients were enrolled. Median age was 15 years; Burkitt lymphoma, Burkitt leukemia, and Burkitt-like lymphoma (total: 45%) and diffuse large B-cell lymphoma/primary mediastinal B-cell lymphoma (51%) were the most common subtypes. At the preplanned interim analysis, median EFS was 6.1 vs 7.0 months with ibrutinib plus RICE/RVICI vs RICE/RVICI, respectively (hazard ratio, 0.9; 90% confidence interval, 0.5-1.6; P = .387); further enrollment was ceased. With ibrutinib plus RICE/RVICI vs RICE/RVICI, median overall survival was 14.1 vs 11.1 months, overall response rate was 69% vs 81%, and 46% vs 44% proceeded to stem cell transplantation. In both treatment arms, 100% of patients experienced grade ≥3 treatment-emergent adverse events. No EFS benefit was seen with ibrutinib. Salvage was generally poor in patients who received prior rituximab, regardless of treatment arm. No new safety signals were observed. Ibrutinib exposure in pediatric patients fell within the target range of exposure in adults. Trial is registered on www.clinicaltrials.gov (NCT02703272).
引用
- Burke GAA, Vinti L, Kabickova E, et al. Ibrutinib plus RICE or RVICI for relapsed/refractory mature B-cell non-Hodgkin lymphoma in children and young adults: SPARKLE trial. Blood Adv. 2023. PMID: 36541957. doi:10.1182/bloodadvances.2022008802
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。